Brain Tumor Res Treat.  2024 Apr;12(2):87-92. 10.14791/btrt.2023.0040.

Patients With Hemangioblastoma: Mood Disorders and Sleep Quality

• Riazi A
• Emaeillou Y
• Najafi N
• Hoseinimanesh M
• Ashkaran MI
• Tehrani DS

• KMID: 2555866
• DOI: http://doi.org/10.14791/btrt.2023.0040

Abstract

Background
Sleep has confirmed physical, psychological, and behavioral benefits, and disruptions can result in disturbances in these states. Moreover, it can be linked bidirectionally with susceptibility to and the subsequent status of brain tumors. The current study examined mood disorders and sleep quality before and after surgery for hemangioblastoma brain tumors.
Methods
Thirty-two patients diagnosed with hemangioblastoma brain tumors between 2017 and 2023 underwent surgical treatment. The Karnofsky Performance Status and ECOG performance status scales, the Brunel Mood Scale, the Morningness-Eveningness Questionnaire, and the MiniSleep Questionnaire were employed to assess the patients.
Results
The findings indicate that after surgery, sleep quality and mood disorders, including tension, vigor, and depression, did not exhibit significant differences in these patients (p>0.05). However, tension, vigor, depression, and sleep quality did have a significant impact on their functional status post-surgery (p<0.05).
Conclusion
Depression is the significant mood factor in patients with brain tumors that impact their functional status. In this context, it is recommended that psychological therapies be considered for them, alongside conducting more comprehensive and in-depth studies on psychological disorders in patients with brain tumors.

Keyword

Hemangioblastoma; Mood disorders; Sleep quality; Brain tumor; Anxiety

Reference

1. Klingler JH, Gläsker S, Bausch B, Urbach H, Krauss T, Jilg CA, et al. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst. 2020; 36:2537–2552. PMID: 32507909.

2. Yin X, Duan H, Yi Z, Li C, Lu R, Li L. Incidence, prognostic factors and survival for hemangioblastoma of the central nervous system: analysis based on the surveillance, epidemiology, and end results database. Front Oncol. 2020; 10:570103. PMID: 33014882.

3. Yoda RA, Cimino PJ. Neuropathologic features of central nervous system hemangioblastoma. J Pathol Transl Med. 2022; 56:115–125. PMID: 35501672.

4. Lopes Dos Santos A, Trevas S, Rosado ML. A challenge in diagnosis of cerebellar hemangioblastoma. Cureus. 2022; 14:e21713. PMID: 35242478.

5. Tamura K, Kanazashi Y, Kawada C, Sekine Y, Maejima K, Ashida S, et al. Variant spectrum of von Hippel-Lindau disease and its genomic heterogeneity in Japan. Hum Mol Genet. 2023; 32:2046–2054. PMID: 36905328.

6. Sundblom J, Skare TP, Holm O, Welin S, Braun M, Nilsson P, et al. Central nervous system hemangioblastomas in von Hippel-Lindau disease: total growth rate and risk of developing new lesions not associated with circulating VEGF levels. PLoS One. 2022; 17:e0278166. PMID: 36441756.

7. Pan J, Jabarkheel R, Huang Y, Ho A, Chang SD. Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis. J Neurooncol. 2018; 137:11–22. PMID: 29204841.

8. Ahadi M, Zham H, Rakhshan A, Rafizadeh M, Talebi Bayazi D, Baikpour M, et al. Hemangioblastoma of the central nervous system: a case series of patients surgically treated at Shohada-e-Tajrish Hospital, Tehran, Iran during 2004-2014. Iran J Child Neurol. 2019; 13:163–169.

9. Madhusoodanan S, Ting MB, Farah T, Ugur U. Psychiatric aspects of brain tumors: a review. World J Psychiatry. 2015; 5:273–285. PMID: 26425442.

10. Ghandour F, Squassina A, Karaky R, Diab-Assaf M, Fadda P, Pisanu C. Presenting psychiatric and neurological symptoms and signs of brain tumors before diagnosis: a systematic review. Brain Sci. 2021; 11:301. PMID: 33673559.

11. Dantas F, Raso JL, Braga PSG, Botelho RV, Dantas FLR. Aggressive dissemination of central nervous system hemangioblastoma without association with von Hippel–Lindau disease: a case report and literature review. Surg Neurol Int. 2022; 13:358. PMID: 36128137.

12. Hejazi A, Bashian A, Mousavi NB. Death due to hemangioblastoma cerebellar tumor with psychotic manifestation: a case report. YAFTE. 2008; 10:71–74.

13. Yıldız Çeltek N, Süren M, Demir O, Okan İ. Karnofsky Performance Scale validity and reliability of Turkish palliative cancer patients. Turk J Med Sci. 2019; 49:894–898. PMID: 31192546.

14. Azam F, Latif MF, Farooq A, Tirmazy SH, AlShahrani S, Bashir S, et al. Performance status assessment by using ECOG (Eastern Cooperative Oncology Group) score for cancer patients by oncology healthcare professionals. Case Rep Oncol. 2019; 12:728–736. PMID: 31616281.

15. Ibáñez V, Silva J, Cauli O. A survey on sleep assessment methods. PeerJ. 2018; 6:e4849. PMID: 29844990.

16. Panjeh S, Pompeia S, Archer SN, Pedrazzoli M, von Schantz M, Cogo-Moreira H. What are we measuring with the Morningness-Eveningness Questionnaire? Exploratory factor analysis across four samples from two countries. Chronobiol Int. 2021; 38:234–247. PMID: 32993374.

17. Hasan MM, Khan MHA. Bangla version of the Brunel Mood Scale (BRUMS): validity, measurement invariance and normative data in non-clinical sample. Heliyon. 2022; 8:e09666. PMID: 35734562.

18. Giovagnoli AR. Investigation of cognitive impairments in people with brain tumors. J Neurooncol. 2012; 108:277–283. PMID: 22392124.

19. Taphoorn MJ, Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004; 3:159–168. PMID: 14980531.

20. Mukand JA, Blackinton DD, Crincoli MG, Lee JJ, Santos BB. Incidence of neurologic deficits and rehabilitation of patients with brain tumors. Am J Phys Med Rehabil. 2001; 80:346–350. PMID: 11327556.

21. Leonetti A, Puglisi G, Rossi M, Viganò L, Conti Nibali M, Gay L, et al. Factors influencing mood disorders and health related quality of life in adults with glioma: a longitudinal study. Front Oncol. 2021; 11:662039. PMID: 34094955.

22. Tibbs MD, Huynh-Le MP, Reyes A, Macari AC, Karunamuni R, Tringale K, et al. Longitudinal analysis of depression and anxiety symptoms as independent predictors of neurocognitive function in primary brain tumor patients. Int J Radiat Oncol Biol Phys. 2020; 108:1229–1239. PMID: 32634542.

23. Sharma A, Das AK, Jain A, Purohit DK, Solanki RK, Gupta A. Study of association of various psychiatric disorders in brain tumors. Asian J Neurosurg. 2022; 17:621–630. PMID: 36570750.

24. Pidani AS, Siddiqui AR, Azam I, Shamim MS, Jabbar AA, Khan S. Depression among adult patients with primary brain tumour: a cross-sectional study of risk factors in a low–middle-income country. BMJ Open. 2020; 10:e032748.